modelSulfaphenazole
Extends from Pharmacolibrary.Drugs.ATC.J.J01ED08.
Information
| name: | Sulfaphenazole | |
| ATC code: | J01ED08 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 14 | L |
| clearance: | 0.7 | L/h |
| other parameters in model implementation | ||
Sulfaphenazole is a sulfonamide antibacterial agent used historically for the treatment of bacterial infections. It belongs to the class of sulfonamides, which act by inhibiting bacterial folic acid synthesis. Due to the development of more effective and safer antibiotics, sulfaphenazole is rarely used clinically today and is not approved for contemporary therapeutic use in most regions. It is of particular interest in pharmacology as a potent and selective inhibitor of cytochrome P450 2C9 (CYP2C9) for research purposes.
Pharmacokinetics
Pharmacokinetic parameters estimated for a typical adult after a single oral dose, as reported in literature on healthy male volunteers.
References
Veronese, ME, et al., & Birkett, DJ (1990). Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical pharmacology and therapeutics 47(3) 403–411. DOI:10.1038/clpt.1990.46 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2311340
Zi, J, et al., & Chen, C (2010). Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. Drug metabolism and pharmacokinetics 25(4) 343–350. DOI:10.2133/dmpk.dmpk-10-rg-009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20814155
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)